Nine carbapenem-resistant Escherichia coli isolates harboring Klebsiella pneumoniae carbapenemase (KPC)-2 or KPC-3 enzymes were identified in patients residing in 7 distinct long-term care facilities. Cefotaxime-hydrolyzing (CTX-M)-type beta-lactamases were also documented in 3 isolates. The identification of these enzymes in patients staying in long-term care facilities should be of great concern to all components of health care systems.

No abstract

A surveillance study to identify patients from the community with Escherichia coli resistant to broadspectrum cephalosporins discovered two isolates that were also resistant to polymyxin B and colistin. One isolate from a patient in the community and a second from a patient who received multiple courses of polymyxin B also possessed a CTX-M-15 enzyme. Resistance to cationic peptides in E. coli is unusual, and testing for susceptibility to these agents should be performed.Clinical infections due to multidrug-resistant, extremely drug-resistant, and panresistant strains of Gram-negative bacteria have been steadily increasing over the past decade (1,2,6,13,14). While strains resistant to polymyxin B and colistin (polymyxin E) have been reported for a number of Gramnegative species, clinical isolates of Escherichia coli resistant to these agents have been identified rarely (7, 15). We report here two cases in which polymyxin B-and colistin-resistant E. coli isolates were identified. One was from a surveillance study of 90 E. coli single-patient isolates resistant to broad-spectrum cephalosporins that was conducted from March 2009 through September 2009, and the second isolate was identified in May 2010.The first strain was isolated from an 83-year-old female living at home with a past medical history of hypertension and hyperlipidemia and a remote history of a brain mass that required a resection and radiation therapy. She presented to the emergency department with fever, chills, nausea, bilateral lower extremity erythema, and a white blood cell (WBC) count of 13,000 and was admitted with a diagnosis of cellulitis. Blood cultures and urinalysis were performed. The patient was treated with vancomycin and piperacillin-tazobactam, followed by vancomycin and ampicillin-sulbactam. Urinalysis revealed positive leukocyte esterase with 10 to 20 WBCs per high-power field. Urine cultures yielded 50,000 colonies of E. coli which were identified and for which MICs were determined by the clinical microbiology laboratory using BD Phoenix NMIC/ID-123 panels (Becton, Dickinson and Company, Sparks, MD). Isolates were resistant to ceftriaxone (MIC, 8 g/ml), levofloxacin (MIC, Ͼ4 g/ml), and trimethoprim-sulfamethoxazole (MIC, Ͼ2/38 g/ml) and susceptible to meropenem (MIC, Յ1 g/ml). Isolates were resistant to polymyxin B and colistin by broth microdilution according to CLSI guidelines (5) and Etest methodology performed according to the manufacturer's specifications (bioMérieux North America) ( Table 1). A renal sonogram showed no hydronephrosis, but the patient did have a distended bladder and was unable to void at the time of sonogram. The patient was treated with 50 mg of nitrofurantoin every 8 h for 7 days. In addition, the isolate harbored a CTX-M-15 extended-spectrum-␤-lactamase when analyzed by PCR as previously described (13). Review of the patient's past medical history revealed no identifiable risk factors, including recent hospital admission and recent antibiotic use, for the isolation of polymyxin B-resistant E. coli.The se...

Klebsiella pneumoniae isolates harboring KPC enzymes have been identified in many geographical areas since 2001. Numerous problems exist in the detection and treatment of patients with such isolates. The clinical characteristics and molecular epidemiology associated with 12 randomly chosen patients in whom these enzymes were detected by molecular methods are described. This is the first description of the identification of carbapenem-resistant K. pneumoniae isolates harboring KPC beta-lactamases at the Veterans Administration Hospital in New Jersey (VA NJHCS). Because recognition of carbapenem resistance in K. pneumoniae due to KPC enzymes can only be achieved by molecular methods, detection in the Clinical Microbiology Laboratory by routine methods will continue to be difficult, leading to dilemmas in treatment.

No abstract